Full-Time

Ventilator/ Respiratory Systems Principal Controls Engineer

Third Pole

Third Pole

11-50 employees

Develops portable nitric oxide therapies

No salary listed

Waltham, MA, USA

In Person

Category
Electrical Engineering (1)
Required Skills
C/C++
Requirements
  • Master’s degree in electrical or computer engineering or related specialization, and 10+ years of related experience
  • Experience with ventilators and/or respiratory applications
  • Demonstrated experience designing, implementing, tuning and analyzing high accuracy, multi-sensor control circuits and systems, including high-performance PID feedback and open-loop controls
  • Experience implementing software/firmware control algorithms in C language on embedded, real-time systems
  • Experience with digital and analog electrical circuits
  • Proven ability to engage effectively in risk analysis including FMEA
  • Demonstrated strength in judgment, decision making, and critical thinking
  • Excellent written and verbal communication
  • Demonstrated strength in building relationships at all levels of an organization
Responsibilities
  • Architect electro-mechanical subsystems and pneumatic for Nitric oxide generation, gas delivery control, and safety control
  • Understand analog and digital circuits for a complex system that generates nitric oxide gas, controls gas delivery, includes high voltage generation, current sensors, pneumatic control, environmental sensors, and gas delivery mechanisms
  • Generates and implements software/firmware algorithms in C language including PID control loops for embedded software control and monitoring of complex systems, therapy delivery control, Nitric Oxide generation, and pneumatics
  • Utilizes technical expertise to contribute to the development of system architectures for respiratory devices. Uses modeling, hardware-in-the-loop simulation and actual devices to develop, debug and test complex systems to meet required performance
  • Develops and models complex cross-functional systems
  • Performs advanced risk analyses using FMEA and fault tree methods. Works with other engineering disciplines to develop, implement, and verify system solutions
  • Evaluates product performance on an on-going basis and initiates and evaluates required changes to the design to improve and optimize performance
  • Interfaces with internal and external clinicians, physicians and thought leaders to create innovative products and features
  • Ensures adherence to company quality system, product specifications, industry standards, and quality and regulatory procedures and requirements
  • Maintains accurate documentation of concepts, designs, drawings, and processes through lab notebooks or other methods
Desired Qualifications
  • PhD. in Electrical or computer engineering or related specialization
  • Experience in software-based electromechanical medical device development
  • Experience with statistical process control
  • Experience with pneumatic systems and related components, particularly flow controllers
  • Experience with Python, Jupyter, and data acquisition systems
  • Experience performing design of experiments
  • ISO 14971, IEC 60601, IEC 62304
  • Well-versed in medical product R&D and clinical/regulatory process

Third Pole Therapeutics develops medical devices and therapies for heart and lung conditions. Its flagship portable inhaled nitric oxide device delivers nitric oxide gas to improve blood flow and oxygen delivery, while eNOfit is a wearable platform that continuously and controllably administers nitric oxide. Revenue comes from selling devices to hospitals and through partnerships with other medical companies, and the company differentiates itself by combining portable NO delivery with a wearable drug-delivery platform and maintaining strict quality and regulatory standards (ISO 13485:2016). The goal is to improve patient outcomes and broaden treatment options in cardiopulmonary medicine by developing, manufacturing, and commercializing advanced nitric oxide therapies.

Company Size

11-50

Company Stage

Debt Financing

Total Funding

$106.4M

Headquarters

Waltham, Massachusetts

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Larger randomized placebo-controlled trials planned post-2024 could establish efficacy for home and travel use.
  • Expanding indications beyond hypoxic respiratory failure to COPD, cystic fibrosis, and critical infections.
  • $600 million hospital iNO market plus emerging ambulatory segment creates significant revenue opportunity.

What critics are saying

  • Vero Biotech's iNOvyn system dominates 70% of hospital market with established FDA approval and partnerships.
  • eNOfit wearable may fail larger efficacy trials due to inconsistent NO dosing during patient mobility.
  • Strategic investor from 2022 $32M round may demand liquidity as $10M exempt offering signals funding drought.

What makes Third Pole unique

  • Wearable, tankless NO generator using pulsed electrical discharge from air eliminates compressed gas logistics.
  • FDA-validated eNOfit early feasibility study demonstrates safety for ambulatory PH-ILD treatment beyond hospitals.
  • Portable platform expands iNO access to underserved populations lacking hospital infrastructure or affordability.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Mental Health Support

Remote Work Options

Flexible Work Hours

Conference Attendance Budget

Professional Development Budget

Stock Options

401(k) Retirement Plan

401(k) Company Match

Health Insurance

Dental Insurance

Vision Insurance

Disability Insurance

Life Insurance

Paid Vacation

Paid Holidays

Paid Sick Leave

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Professional Certification Support

Tuition Reimbursement

Training Programs

Mentorship Program

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

0%

2 year growth

-3%
intelligence360
Apr 8th, 2024
Third Pole Has Filed A Notice Of An Exempt Offering Of Securities To Raise $10 Million In New Equity And Debt Financing.

Third Pole has filed a notice of an exempt offering of securities to raise $10 Million in New Equity and Debt Financing. Third Pole has filed a notice of an exempt offering of securities to raise $10 Million in New Equity and Debt Financing.According to filings with the U.S. Securities and Exchange Commission, Third Pole is raising up to $10,000,000.00 in new funding. Sources indicate that as part of senior management President, Basil Athenson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About Third PoleThird Pole, Inc. is a US-based company developing next generation life-saving cardiopulmonary therapies. We are building on our teams legacy in inhaled nitric oxide (NO), the current standard of care, to develop next generation life-saving heart and lung therapies

Pulmonary Hypertension News
Dec 13th, 2023
Early study of inhaled nitric oxide delivery system doses 1st patient

In 2017, Third Pole won a Johnson & Johnson Innovation award for the iNO-generating device.

BioSpace
Dec 15th, 2022
Third Pole Therapeutics Receives $32M Strategic Equity Investment to Accelerate its Tankless Inhaled Nitric Oxide (iNO) Platform | BioSpace

Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator.

Benzinga
Dec 14th, 2022
Third Pole Therapeutics Receives $32M Strategic Equity Investment To Accelerate Its Tankless Inhaled Nitric Oxide (Ino) Platform

Funding will support the final development phase prior to planned 2023 FDA submission of the company's "breakthrough" designated eNOcare™ hospital deviceWALTHAM, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator.Bill Athenson, CEO of Third Pole, stated, "We are thrilled to receive this investment, which raises Third Pole Therapeutics' series B financing and commitments to date to over $85M. I am particularly pleased to welcome this strategic investor and partner given our closely aligned missions. This investment and partnership will accelerate the entry of eNOcare™, our advanced portable inhaled nitric oxide (iNO) device, into the iNO hospital market." Mr. Athenson continued, "This significant investment in Third Pole Therapeutics follows considerable diligence of our engineering and regulatory readiness and serves as a strong endorsement of our technology and team's ability to deliver critical care systems that exceed safety and performance requirements established by regulatory bodies and the most demanding care professionals. We are targeting a 2023 FDA submission for our eNOcare™ hospital system into the existing and underpenetrated $600 million iNO hospital market."Bill Heiden, Third Pole's Chairman added, "This strategic investment in Third Pole Therapeutics is directly aligned with both organization's mission to advance unique, disruptive, cost-effective solutions that improve outcomes in heart and lung-failure patients

Bizjournals
Feb 26th, 2021
Form D Friday: Facebook co-founder invests in Cambridge energy startup

Form D Friday is a Boston Business Journal feature highlighting regulatory filings from Boston-area companies raising capital for new projects or expanding their businesses.